in vitro News and Research

RSS

Study explores vaccine effectiveness against the SARS-CoV-2 Omicron variant in patients receiving hemodialysis

A new study studied the clinical impact of SARS-CoV-2 Omicron infection, and vaccine effectiveness, in patients undergoing in-center hemodialysis (IC-HD).

28 Jan 2022

γ’ fibrinogen as a disease progression marker for COVID-19

Levels of the inflammatory biomarker gamma prime fibrinogen (γ' Fbg) varies according to severity in COVID-19 patients.

28 Jan 2022

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Researcher discusses several promising therapeutic candidates that have been proposed for the treatment of patients infected with the Omicron variant.

28 Jan 2022

Study demonstrates minimally invasive, aerosolized vaccine candidate to combat SARS-CoV-2

This study showed inhalable Covid-19 mimetic particle carriers as potential, versatile, aerosolizable COVID-19 vaccine candidates if worked on with continued optimization and refinement.

28 Jan 2022

SARS-CoV-2 virus may be shed for much longer periods by some infected patients, study shows

In a 38-year-old man who manifested mild symptoms of COVID-19 for 20 days, the novel coronavirus continued to be detected in his organism and to undergo mutations for 232 days.

27 Jan 2022

COVID-19 vaccination does not affect fertility outcomes in patients undergoing in-vitro fertilization

Vaccination against COVID-19 did not affect fertility outcomes in patients undergoing in-vitro fertilization (IVF), a new study has found.

27 Jan 2022

Macromolecular gel with therapeutic payload could halt or slow post-traumatic osteoarthritis

Osteoarthritis affects over 32 million Americans, levying a huge cost on society. Unfortunately, other than analgesics, no pharmaceutical therapy exists that can slow or halt disease progression of a major subset of OA: post-traumatic osteoarthritis (PTOA).

26 Jan 2022

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

In a new study, researchers evaluated SARS-CoV-2 vaccination-induced T cell responses cross-recognition among the early and novel SARS-CoV-2 variants.

26 Jan 2022

Gene therapy can provide long-lasting therapeutic benefit in Huntington's disease

Gene therapy targeting the messenger RNA (mRNA) of the mutated huntingtin gene (HTT) can provide long-lasting therapeutic benefit in Huntington's disease after a single administration.

25 Jan 2022

Third dose of BNT162b2 vaccine protects against Omicron hospitalizations

A new study assesses the effectiveness of two and three doses of the BNT162b2 vaccine against Omicron-related hospitalizations.

25 Jan 2022

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

A new study has focused on the identification, in vitro binding, and potent neutralizing activity of STI-9167 (plutavimab) against live viruses and pseudotype viruses.

25 Jan 2022

Impact of a third BNT162b2 dose on SARS-CoV-2 Omicron variant

In a new study, researchers assessed the extent and duration of the neutralization of SARS-CoV-2 Omicron variant of concern after the administration of two and three doses of the BNT162b2 mRNA vaccine.

25 Jan 2022

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

A new study investigated SARS-CoV-2 spike protein responses targeted by cross-reactive T cells that were isolated from convalescent COVID-19 individuals along with previously uninfected donors.

25 Jan 2022

In Portugal risk of hospitalization from Omicron is 75% lower than Delta

Researchers from Portugal reported a 75% risk reduction in hospitalizations for individuals infected with Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared to the Delta variant and a shorter length of stay and lower mortality if hospitalization does occur. Their paper is currently available on the medRxiv* preprint server while undergoing peer review.

24 Jan 2022

Investigating Omicron’s fitness and replicative potential compared with earlier SARS-CoV-2 variants using organoids

This study examined the shedding, fitness, and pathogenicity of SARS-CoV-2 VOCs using human airway and alveolar organoids.

24 Jan 2022

Human endogenous retrovirus type W envelope protein found to be a biomarker of COVID-19 severity

A new study revealed that the expression of HERV-W envelope protein (ENV) in lymphoid cells from COVID-19 patients correlated with disease outcome making them biomarkers of lymphocyte exhaustion.

24 Jan 2022

Gene replacement therapy could help mend a broken heart, study suggests

How can you mend a broken heart? According to researchers from Japan, in some cases gene replacement therapy just might do the trick.

24 Jan 2022

An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

In a recent study posted to the bioRxiv* preprint server, researchers developed a novel bioinformatic algorithm to predict host cleavage targets of the SARS-CoV-2 3C-like protease (3CLPro).

23 Jan 2022

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals authorized for emergency use by the United States Food and Drug Administration (FDA) for their in vitro potency against several SARS-CoV-2 variants, including the currently dominant Omicron train.

23 Jan 2022

Paxlovid provides a glimpse into the future against SARS-CoV-2

A recent study reveals that nirmatrelvir is potent and effective against the SARS-CoV-2 Omicron variant.

23 Jan 2022

in vitro News and Research

Study explores vaccine effectiveness against the SARS-CoV-2 Omicron variant in patients receiving hemodialysis

γ’ fibrinogen as a disease progression marker for COVID-19

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Study demonstrates minimally invasive, aerosolized vaccine candidate to combat SARS-CoV-2

SARS-CoV-2 virus may be shed for much longer periods by some infected patients, study shows

COVID-19 vaccination does not affect fertility outcomes in patients undergoing in-vitro fertilization

Macromolecular gel with therapeutic payload could halt or slow post-traumatic osteoarthritis

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

Gene therapy can provide long-lasting therapeutic benefit in Huntington's disease

Third dose of BNT162b2 vaccine protects against Omicron hospitalizations

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

Impact of a third BNT162b2 dose on SARS-CoV-2 Omicron variant

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

In Portugal risk of hospitalization from Omicron is 75% lower than Delta

Investigating Omicron’s fitness and replicative potential compared with earlier SARS-CoV-2 variants using organoids

Human endogenous retrovirus type W envelope protein found to be a biomarker of COVID-19 severity

Gene replacement therapy could help mend a broken heart, study suggests

An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

Paxlovid provides a glimpse into the future against SARS-CoV-2

Driving innovation in drug discovery with in vitro biology solutions eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News